Overview
PDS Biotech’s oncology pipeline leverages the Versamune® and Versamune® plus PDS0301 platform technologies in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies.
| Products | Indication | Combination | PC | P1 | P2 | P3 | R | PARTNER(S) |
|---|---|---|---|---|---|---|---|---|
| Clinical (Lead) | ||||||||
| PDS0101 (HPV)/ VERSATILE-002 Learn more |
Recurrent or metastatic HPV16-positive head and neck cancer | KEYTRUDA® (Standard of Care) |
|
|
 |
|||
| Arm 1: ICI naïve | ||||||||
| Arm 2: ICI refratory | ||||||||
| IIT Studies | ||||||||
| PDS0101 (HPV)/ IMMUNOCERV Learn more |
1st line treatment of locally advanced (IB3-IVA) cervical cancer | Chemo-radiation (Standard of Care) |
|
|
 |
|||
| PDS0101 (HPV)/ Mayo Clinic Learn more |
Pre-metastatic HPV-positive oropharyngeal cancer (OPSCC) | KEYTRUDA® (Standard of Care) |
|
|
 |
|||
| Arm 1: PDS0101 monotherapy | ||||||||
| Arm 2: PDS0101 + KEYTRUDA® | ||||||||
| PDS0301/ PDS0101 |
HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers | Immune Checkpoint Inhibitor |
|
|
 |
|||
| Arm 1: ICI naïve | ||||||||
| Arm 2: ICI refratory | ||||||||
| PDS0301 | Advanced Kaposi Sarcoma | Monotherapy |
|
|
|
|||
| PDS0301 | Metastatic Castration sensitive and Castration Resistant Prostate Cancer | Docetaxal |
|
|
|
|||
| PDS0301 | Localized High and Intermediate Risk Prostate Cancer | Radiation Therapy |
|
|
|
|||
| PDS0301 | ICI Refractory HPV-related, colon and small-bowel cancer | HDAC Inhibitor |
|
|
|
|||
| Preclinical Candidates | ||||||||
| PDS0102 (TARP) |
TARP-positive AML, prostate and breast cancers | TBD |
|
|
|
|||
| PDS0103 (MUC1) |
MUC1-positive breast, colon, lung, ovarian and other cancers | TBD |
|
|
|
|||
| PDS0104 (TRP2) |
Melanoma | TBD |
|
|
||||
PDS Biotech Funded  |
Partner Co-Funded  |
|||||||